MarginScan™
for Skin Cancer
Non-melanoma skin cancers are the most common cancers worldwide, yet current surgical approaches force tradeoffs between speed, cost, and tissue preservation.
MarginScan™ enables histology-like margin control in minutes, without freezing tissue. Mohs surgeons can use it to obtain rapid insight; MarginScan doesn't impact the tissue, and traditional frozen section histology can follow.
Compared to traditional Mohs surgery, MarginScan offers:
- Faster, more predictable procedures
- Reduced cost and resource intensity
- Dramatically improved patient experience
- Lower recurrence risk compared to simple excision
- Traditional Mohs-level outcomes.
Commercial Status: A letter of intent for exclusive U.S. distribution has been signed with Epredia, PHC Holdings' cancer diagnostics division. A 2027 launch is anticipated.